v3.26.1
Organization and Business Operations (Details Narrative)
$ / shares in Units, $ in Thousands
 1 Months Ended 12 Months Ended
Jan. 25, 2026
USD ($)
$ / shares
shares
Oct. 26, 2025
USD ($)
$ / shares
shares
Sep. 17, 2025
USD ($)
Aug. 05, 2025
Mar. 26, 2025
USD ($)
$ / shares
shares
Sep. 26, 2024
wk
Sep. 04, 2024
May 28, 2024
Feb. 29, 2024
Dec. 31, 2025
USD ($)
Number
shares
Jul. 15, 2026
USD ($)
Dec. 31, 2024
shares
Dec. 19, 2024
Number
Dec. 31, 2023
shares
Dec. 31, 2022
shares
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                              
Common stock, shares outstanding | shares                   76,428,000   59,235,000      
Percentage of patients do not take their medicine as prescribed in real world                   50.00%          
Percentage of patients taking Wegovy (semaglutide injectable) discontinue therapy within first year of treatment                   64.00%          
Percentage of weight loss after exenatide implant therapy for patients whom has high-fat diet-induced obese mice                 20.00%            
Period of sham implant control therapy                 28 days            
Period of specific therapy with a single administration               6 months              
Percentage of liver fat reduction after exenatide implant therapy for patients whom has high-fat diet-induced obese mice             82.00%                
Revenue from Contract with Customer, Including Assessed Tax                   $ 0          
Number of weeks before being randomized to receive a therapy | wk           8                  
Number of weeks for weekly semaglutide injections therapy | wk           9                  
Percentage of patients taking Wegovy (semaglutide injectable) discontinue therapy within second year of treatment                   76.00%          
Percentage of approximate weight loss achieved in preclinical data       20.00%           20.00%          
Number of equity purchase agreements | Number                   3          
Committed capital                     $ 12,600        
AUSTRALIA                              
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                              
Screening and enrollment of liberate-1, number of study centre | Number                         2    
Entity Affiliated With Directors [Member] | Private Placement [Member]                              
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                              
Gross proceeds from the private sale transaction         $ 8,250                    
Common share price | $ / shares         $ 1.12                    
Shares, Issued | shares         7,366,071                    
Think Equity Llc [Member] | Placement Agency Agreement [Member]                              
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                              
Sale of common stock authorized in direct offering | shares   6,000,000                          
Proceeds from issuance of common stock in connection with direct offering gross   $ 9,700                          
Subsequent Event [Member] | Think Equity Llc [Member] | Placement Agency Agreement [Member]                              
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                              
Sale of common stock authorized in direct offering | shares 1,689,200                            
Sale of common stock at direct offering price per share | $ / shares $ 1.48                            
Proceeds from issuance of common stock in connection with direct offering gross $ 2,500                            
Common Stock [Member]                              
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                              
Common stock, shares outstanding | shares                   76,428,000   59,235,000   51,031,000  
Common Stock [Member] | Entity Affiliated With Directors [Member]                              
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                              
Gross proceeds from the private sale transaction   $ 6,000                          
Common share price | $ / shares   $ 1.62                          
Shares, Issued | shares   3,703,703                          
Common Stock [Member] | Subsequent Event [Member] | Entity Affiliated With Directors [Member] | Private Placement [Member]                              
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                              
Gross proceeds from the private sale transaction $ 2,000                            
Common share price | $ / shares $ 1.48                            
Shares, Issued | shares 1,351,351                            
Cortigent, Inc. [Member]                              
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                              
Common stock, shares outstanding | shares                             5,000,000
Transition funding loan     $ 1,500                        
Cortigent, Inc. [Member] | Promissory note [Member]                              
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                              
Issuance of promissory note     $ 2,000                        
Promissory note term     5 years                        
Promissory note interest rate     5.00%                        
Minimum [Member]                              
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                              
Period for delivering therapeutic drug levels                   6 months          
License and Supply Agreement [Member] | Okava Pharmaceuticals, Inc. [Member]                              
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                              
Regulatory milestone payments added                   $ 5,000